These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1150 related articles for article (PubMed ID: 21855208)

  • 41. Comparing morbidity and cancer control after 3D-conformal (70/74 Gy) and intensity modulated radiotherapy (78/82 Gy) for prostate cancer.
    Dolezel M; Odrazka K; Zouhar M; Vaculikova M; Sefrova J; Jansa J; Paluska P; Kohlova T; Vanasek J; Kovarik J
    Strahlenther Onkol; 2015 Apr; 191(4):338-46. PubMed ID: 25589224
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination of IG-IMRT and permanent source prostate brachytherapy in patients with organ-confined prostate cancer: GU and GI toxicity and effect on erectile function.
    Valakh V; Kirichenko A; Miller R; Sunder T; Miller L; Fuhrer R
    Brachytherapy; 2011; 10(3):195-200. PubMed ID: 21030319
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy.
    Valdagni R; Italia C; Montanaro P; Lanceni A; Lattuada P; Magnani T; Fiorino C; Nahum A
    Radiother Oncol; 2005 Apr; 75(1):74-82. PubMed ID: 15878104
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy.
    Ost P; Cozzarini C; De Meerleer G; Fiorino C; De Potter B; Briganti A; Nagler EV; Montorsi F; Fonteyne V; Di Muzio N
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):960-5. PubMed ID: 22172901
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking.
    Ghadjar P; Vock J; Vetterli D; Manser P; Bigler R; Tille J; Madlung A; Behrensmeier F; Mini R; Aebersold DM
    Radiat Oncol; 2008 Oct; 3():35. PubMed ID: 18937833
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term outcomes of IMRT for breast cancer: a single-institution cohort analysis.
    McDonald MW; Godette KD; Butker EK; Davis LW; Johnstone PA
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1031-40. PubMed ID: 18440727
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison and limitations of DVH-based NTCP models derived from 3D-CRT and IMRT data for prediction of gastrointestinal toxicities in prostate cancer patients by using propensity score matched pair analysis.
    Troeller A; Yan D; Marina O; Schulze D; Alber M; Parodi K; Belka C; Söhn M
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):435-43. PubMed ID: 25636766
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancer.
    Jereczek-Fossa BA; Maucieri A; Marvaso G; Gandini S; Fodor C; Zerini D; Riva G; Alessandro O; Surgo A; Volpe S; Fanetti G; Arculeo S; Zerella MA; Parisi S; Maisonneuve P; Vavassori A; Cattani F; Cambria R; Garibaldi C; Starzyńska A; Musi G; De Cobelli O; Ferro M; Nolè F; Ciardo D; Orecchia R
    Med Oncol; 2018 Nov; 36(1):9. PubMed ID: 30483899
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields.
    Jani AB; Su A; Correa D; Gratzle J
    Prostate Cancer Prostatic Dis; 2007; 10(1):82-6. PubMed ID: 16983394
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients.
    Wortel RC; Incrocci L; Pos FJ; Lebesque JV; Witte MG; van der Heide UA; van Herk M; Heemsbergen WD
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):737-44. PubMed ID: 25752386
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer.
    Vora SA; Wong WW; Schild SE; Ezzell GA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1053-8. PubMed ID: 17398023
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of clinical outcomes and toxicity in endometrial cancer patients treated with adjuvant intensity-modulated radiation therapy or conventional radiotherapy.
    Chen CC; Wang L; Lu CH; Lin JC; Jan JS
    J Formos Med Assoc; 2014 Dec; 113(12):949-55. PubMed ID: 24144528
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis.
    Briganti A; Wiegel T; Joniau S; Cozzarini C; Bianchi M; Sun M; Tombal B; Haustermans K; Budiharto T; Hinkelbein W; Di Muzio N; Karakiewicz PI; Montorsi F; Van Poppel H
    Eur Urol; 2012 Sep; 62(3):472-87. PubMed ID: 22633803
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chronic genitourinary and gastrointestinal toxicity of prostate cancer patients undergoing pelvic radiotherapy with intensity-modulated versus 4-field technique.
    Su AW; Jani AB
    Am J Clin Oncol; 2007 Jun; 30(3):215-9. PubMed ID: 17551295
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer.
    Vora SA; Wong WW; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
    J Urol; 2013 Aug; 190(2):521-6. PubMed ID: 23415964
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Short-course, intensity-modulated radiotherapy for localized prostate cancer.
    Kupelian PA; Willoughby TR
    Cancer J; 2001; 7(5):421-6. PubMed ID: 11693901
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men agedGómez-Iturriaga Piña A; Crook J; Borg J; Lockwood G; Fleshner N
    Urology; 2010 Jun; 75(6):1412-6. PubMed ID: 20035986
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer.
    Karlsdóttir A; Johannessen DC; Muren LP; Wentzel-Larsen T; Dahl O
    Radiother Oncol; 2004 Apr; 71(1):43-53. PubMed ID: 15066295
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer.
    Lewis SL; Patel P; Song H; Freedland SJ; Bynum S; Oh D; Palta M; Yoo D; Oleson J; Salama JK
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):605-11. PubMed ID: 26867889
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
    Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
    Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.